{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:51:40Z","timestamp":1787964700736,"version":"build-2784847793"},"reference-count":46,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:p>Newborn screening (NBS) for Pompe disease is done through analysis of acid \u03b1-glucosidase (GAA) activity in dried blood spots. When GAA levels are below established cutoff values, then second-tier testing is required to confirm or refute a diagnosis of Pompe disease. This article in the \u201cNewborn Screening, Diagnosis, and Treatment for Pompe Disease\u201d guidance supplement provides recommendations for confirmatory testing after a positive NBS result indicative of Pompe disease is obtained. Two algorithms were developed by the Pompe Disease Newborn Screening Working Group, a group of international experts on both NBS and Pompe disease, based on whether DNA sequencing is performed as part of the screening method. Using the recommendations in either algorithm will lead to 1 of 3 diagnoses: classic infantile-onset Pompe disease, late-onset Pompe disease, or no disease\/not affected\/carrier. Mutation analysis of the GAA gene is essential for confirming the biochemical diagnosis of Pompe disease. For NBS laboratories that do not have DNA sequencing capabilities, the responsibility of obtaining sequencing of the GAA gene will fall on the referral center. The recommendations for confirmatory testing and the initial evaluation are intended for a broad global audience. However, the Working Group recognizes that clinical practices, standards of care, and resource capabilities vary not only regionally, but also by testing centers. Individual patient needs and health status as well as local\/regional insurance reimbursement programs and regulations also must be considered.<\/jats:p>","DOI":"10.1542\/peds.2016-0280d","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T08:36:03Z","timestamp":1498811763000},"page":"S14-S23","source":"Crossref","is-referenced-by-count":35,"title":["The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease"],"prefix":"10.1542","volume":"140","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, and the Division of Genetics, Birth Defects, and Metabolism, Ann & Robert H. Lurie Children\u2019s Hospital, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Kronn","sequence":"additional","affiliation":[{"name":"Department of Pathology and Pediatrics, New York Medical College, Valhalla, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Medical Genetics, National Taiwan University Hospital, and National Taiwan College of Medicine, Taipei, Taiwan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Pompe Disease Newborn Screening Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"issue":"10","key":"2021121007440860800_B1","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe Registry.","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2021121007440860800_B2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"issue":"4","key":"2021121007440860800_B3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"issue":"5","key":"2021121007440860800_B4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline.","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"1","key":"2021121007440860800_B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.","volume":"160C","author":"Bali","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"2021121007440860800_B6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161A","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2021121007440860800_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.c.31324","article-title":"The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.","volume":"160C","author":"Kishnani","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2021121007440860800_B8","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children.","volume":"144","author":"Kishnani","year":"2004","journal-title":"J Pediatr"},{"key":"2021121007440860800_B9","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Hirschhorn","year":"2001","edition":"8th ed."},{"issue":"5","key":"2021121007440860800_B10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"2","key":"2021121007440860800_B11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature.","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"21","key":"2021121007440860800_B12","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/ajmg.a.31936","article-title":"Sibling phenotype concordance in classical infantile Pompe disease.","volume":"143A","author":"Smith","year":"2007","journal-title":"Am J Med Genet A"},{"issue":"5","key":"2021121007440860800_B13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.","volume":"13","author":"Wang","year":"2011","journal-title":"Genet Med"},{"issue":"12","key":"2021121007440860800_B14","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration.","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"issue":"8","key":"2021121007440860800_B15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases.","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"issue":"1","key":"2021121007440860800_B16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajmg.c.31322","article-title":"Toward deconstructing the phenotype of late-onset Pompe disease.","volume":"160C","author":"Sch\u00fcller","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"5","key":"2021121007440860800_B17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mus.21933","article-title":"Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid \u03b1-glucosidase activity.","volume":"43","author":"Bali","year":"2011","journal-title":"Muscle Nerve"},{"issue":"4","key":"2021121007440860800_B18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ymgme.2006.12.006","article-title":"Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots.","volume":"90","author":"Kallwass","year":"2007","journal-title":"Mol Genet Metab"},{"key":"2021121007440860800_B19","first-page":"1993","volume-title":"GeneReviews [Internet]","author":"Leslie","year":"2007"},{"key":"2021121007440860800_B20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/8904_2014_339","article-title":"Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype.","volume":"17","author":"Lee","year":"2014","journal-title":"JIMD Rep"},{"issue":"4","key":"2021121007440860800_B21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.","volume":"262","author":"Montagnese","year":"2015","journal-title":"J Neurol"},{"issue":"4","key":"2021121007440860800_B22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1212\/WNL.52.4.851","article-title":"A diagnostic protocol for adult-onset glycogen storage disease type II.","volume":"52","author":"Ausems","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"2021121007440860800_B23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.21376","article-title":"Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.","volume":"40","author":"Goldstein","year":"2009","journal-title":"Muscle Nerve"},{"issue":"1","key":"2021121007440860800_B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/17530050903460300","article-title":"Enzymatic and molecular strategies to diagnose Pompe disease.","volume":"4","author":"Reuser","year":"2010","journal-title":"Expert Opin Med Diagn"},{"issue":"RR-2","key":"2021121007440860800_B25","first-page":"1","article-title":"Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders.","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"2021121007440860800_B26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymgme.2007.09.006","article-title":"Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.","volume":"93","author":"Winchester","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2021121007440860800_B27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.","volume":"347","author":"Chamoles","year":"2004","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2021121007440860800_B28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.gim.0000217781.66786.9b","article-title":"Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease.","volume":"8","author":"Zhang","year":"2006","journal-title":"Genet Med"},{"issue":"7","key":"2021121007440860800_B29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/2013.jamaneurol.486","article-title":"Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.","volume":"70","author":"Vissing","year":"2013","journal-title":"JAMA Neurol"},{"issue":"1","key":"2021121007440860800_B30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","article-title":"Diagnostic criteria for late-onset (childhood and adult) Pompe disease.","volume":"40","author":"American Association of Neuromuscular & Electrodiagnostic Medicine","year":"2009","journal-title":"Muscle Nerve"},{"issue":"12","key":"2021121007440860800_B31","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/jcp.2005.027045","article-title":"Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre.","volume":"58","author":"Anderson","year":"2005","journal-title":"J Clin Pathol"},{"issue":"2","key":"2021121007440860800_B32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10545-009-9027-4","article-title":"PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease.","volume":"33","author":"Hagemans","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2021121007440860800_B33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.nmd.2011.11.003","article-title":"Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology.","volume":"22","author":"Tsuburaya","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"1\u20132","key":"2021121007440860800_B34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2014.07.014","article-title":"Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry.","volume":"113","author":"Kishnani","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2021121007440860800_B35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2009.03.004","article-title":"High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population.","volume":"97","author":"Kumamoto","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2021121007440860800_B36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymgme.2011.01.006","article-title":"Improved assay for differential diagnosis between Pompe disease and acid \u03b1-glucosidase pseudodeficiency on dried blood spots.","volume":"103","author":"Shigeto","year":"2011","journal-title":"Mol Genet Metab"},{"key":"2021121007440860800_B37","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1007\/s10545-008-0820-2","article-title":"Molecular diagnosis of German patients with late-onset glycogen storage disease type II.","volume":"31","author":"Joshi","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2021121007440860800_B38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mus.24149","article-title":"Blood-based diagnostic testing for Pompe disease: consistency between GAA enzyme activity in dried blood spots and GAA gene sequencing results.","volume":"49","author":"Goldstein","year":"2014","journal-title":"Muscle Nerve"},{"issue":"2","key":"2021121007440860800_B39","first-page":"78","article-title":"Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD).","volume":"32","author":"Toscano","year":"2013","journal-title":"Acta Myol"},{"issue":"5","key":"2021121007440860800_B40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/adc.54.5.362","article-title":"Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy.","volume":"54","author":"Drummond","year":"1979","journal-title":"Arch Dis Child"},{"issue":"10","key":"2021121007440860800_B41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK).","volume":"21","author":"Moat","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2021121007440860800_B42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.17925\/ENR.2014.09.01.83","article-title":"The diagnostic path to Pompe disease.","volume":"9","author":"Bodamer","year":"2014","journal-title":"Eur Neurol Rev"},{"issue":"1","key":"2021121007440860800_B43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.c.31320","article-title":"Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.","volume":"160C","author":"Young","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2021121007440860800_B44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/8904_2014_366","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening.","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep"},{"issue":"7","key":"2021121007440860800_B45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","article-title":"Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy.","volume":"13","author":"Forsha","year":"2011","journal-title":"Genet Med"},{"issue":"3","key":"2021121007440860800_B46","first-page":"202","article-title":"S1.4 Cardiovascular involvement in Pompe disease.","volume":"30","author":"Limongelli","year":"2011","journal-title":"Acta Myol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/140\/Supplement_1\/S14\/1142808\/peds_20160280d.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/140\/Supplement_1\/S14\/1142808\/peds_20160280d.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T03:54:27Z","timestamp":1719287667000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/140\/Supplement_1\/S14\/179261\/The-Initial-Evaluation-of-Patients-After-Positive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":46,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-0280d","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]}}}